Reference List: Beta Agonists

Beta Agonists

Drugs for asthma. Med Lett Drugs Ther. 1999;41:5-10.

Rau JL J; Airway pharmacology. In: Scanlan CL, Wilkins RL, Stoller JK, Eds. Egan's Fundamentals of Respiratory Care. 7 ed. St. Louis: Mosby; 1999.

Aziz I, McFarlane LC, Lipworth BJ. Concomitant inhaled corticosteroid resensitises cardiac beta2- adrenoceptors in the presence of long-acting beta2-agonist therapy. Eur J Clin Pharmacol. 1998;54:377-81.

Beasley R, Nishima S, Pearce N, Crane J. Beta-agonist therapy and asthma mortality in Japan [letter]. Lancet. 1998;351:1406-7.

Bennett ED. Dopexamine: much more than a vasoactive agent [editorial; comment]. Crit Care Med. 1998;26:1621-2.

Cockcroft DW. Inhaled beta2-agonists and airway responses to allergen. J Allergy Clin Immunol. 1998;102:S96-9.

Congleton J, Muers MF. Effect of regular use of high-dose nebulized beta2-agonists on resting energy expenditure, weight, and handgrip strength in patients with chronic airflow limitation. Chest. 1998;113:1588-94.

Corne JM, Linaker CH, Howarth PH, et al. Effect of systemic beta-agonist therapy on IgE production in allergic subjects in vivo. J Allergy Clin Immunol. 1998;102:727-31.

Costello J. Cardiac effects of beta-agonists in patients with COPD [editorial]. Chest. 1998;114:353-4.

Ernst P. Long acting beta 2 agonists and the risk of life threatening asthma [editorial; comment]. Thorax. 1998;53:1-2.

Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J. 1998;11:589-93.

January B, Seibold A, Allal C, et al. Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor. Br J Pharmacol. 1998;123:701-11.

Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med. 1998;158:S146-53.

Kornecki A, Shemie SD. Bronchodilators and RSV-induced respiratory failure: agonizing about beta2 agonists [editorial; comment]. Pediatr Pulmonol. 1998;26:4-5.

Lindmark B. Cardiac risks with beta agonists [letter; comment]. Thorax. 1998;53:1094-5.

Martin RM, Dunn NR, Freemantle SN, Mann RD. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax. 1998;53:558-62.

Molimard M, Naline E, Zhang Y, et al. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J. 1998;11:583-8.

Moore RH, Khan A, Dickey BF. Long-acting inhaled beta2-agonists in asthma therapy. Chest. 1998;113:1095-108.

O'Byrne PM, Gauvreau GM, Wood LJ. Pharmacologic modulation of airway inflammation. Allergy. 1998;53:41-7.

Pillet O, Manier G, Castaing Y. Anticholinergic versus beta 2-agonist on gas exchange in COPD: a comparative study in 15 patients. Monaldi Arch Chest Dis. 1998;53:3-8.

Schmidt W, Hacker A, Gebhard MM, Martin E, Schmidt H. Dopexamine attenuates endotoxin-induced microcirculatory changes in rat mesentery: role of beta2 adrenoceptors. Crit Care Med. 1998;26:1639-45.

Sears MR. Asthma treatment: inhaled beta-agonists. Can Respir J. 1998;5 Suppl A:54A-9A.

Valente S, De Rosa M, Corbo GM, et al. Slow compartment features and gas exchange impairment in mild asthma: effects of beta agonist inhalation. Respiration. 1998;65:40-8.

Weir TD, Mallek N, Sandford AJ, et al. beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med. 1998;158:787-91.

Yates DH, Worsdell M, Barnes PJ. Effect of an inhaled glucocorticosteroid on mast cell and smooth muscle beta 2 adrenergic tolerance in mild asthma. Thorax. 1998;53:110-3.

Zhang XY, Zhu FX, Olszewski MA, Robinson NE. Effects of enantiomers of beta 2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol. 1998;274:L32-8.

Using beta 2-stimulants in asthma. Drug Ther Bull. 1997;35:1-4.

Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med. 1997;155:704-10.

Barnes PJ. Current therapies for asthma. Promise and limitations. Chest. 1997;111:17S-26S.

Beausoleil JL, Weldon DP, McGeady SJ. Beta 2-agonist metered dose inhaler overuse: psychological and demographic profiles. Pediatrics. 1997;99:40-3.

Bjermer L, Larsson L. Long-acting beta(2)-agonists: how are they used in an optimal way? Respir Med. 1997;91:587-91.

D'Urzo AD. Long-acting beta 2-agonists. Role in primary care asthma treatment. Can Fam Physician. 1997;43:1773-7.

Eggleston PA. Are beta-adrenergic bronchodilators safe?[comment]. Pediatrics. 1997;99:729-30.

Finn AF Jr, Thompson CM Jr, Banov CH, et al. Beta2-agonist induced ventricular dysrhythmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome. Ann Allergy Asthma Immunol. 1997;78:230-2.

Flores G, Horwitz RI. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta- analysis. Pediatrics. 1997;100:233-9.

Gillissen A, Wickenburg D, van Zwoll D, et al. Beta-2-agonists have antioxidant function in vitro. 2. The effect of beta-2-agonists on oxidant-mediated cytotoxicity and on superoxide anion generated by human polymorphonuclear leukocytes. Respiration. 1997;64:23-8.

Gillissen A, Jaworska M, Scharling B, et al. Beta-2-agonists have antioxidant function in vitro. 1. Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical. Respiration. 1997;64:16-22.

Kim HJ. Acute therapy for hyperkalemia with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients. J Korean Med Sci. 1997;12:111-6.

Konradova V, Uhlik J, Vajner L, Zocova J. Effect of an adrenergic agonist and a cholinergic antagonist on the airway epithelium. Vet Med (Praha). 1997;42:289-93.

Liggett SB. Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med. 1997;156:S156-62.

Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Drug Saf. 1997;16:295-308.

Maury E, Ioos V, Lepecq B, et al. A paradoxical effect of bronchodilators. Chest. 1997;111:1766-7.

Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax. 1997;52:612-7.

Qing F, Rahman SU, Hayes MJ, et al. Effect of long-term beta2-agonist dosing on human cardiac beta- adrenoceptor expression in vivo: comparison with changes in lung and mononuclear leukocyte beta-receptors. J Nucl Cardiol. 1997;4:532-8.

Sakuma T, Folkesson HG, Suzuki S, et al. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med. 1997;155:506-12.

Salome C, Woolcock A. Effects of beta-agonists on dose-response curves [letter; comment]. Eur Respir J. 1997;10:2434-5.

Stewart AG, Tomlinson PR, Wilson JW. Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of beta 2-adrenoceptor stimulation. Br J Pharmacol. 1997;121:361-8.

Tan S, Hall IP, Dewar J, et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997;350:995-9.

Tibayan FA, Chesnutt AN, Folkesson HG, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997;156:438-44.

Totaro RJ, Raper RF. Epinephrine-induced lactic acidosis following cardiopulmonary bypass. Crit Care Med. 1997;25:1693-9.

Wheatley EC. Treatment of hyperkalaemia [letter; comment]. Br J Hosp Med. 1997;57:171.

Wong AG, O'Shaughnessy AD, Walker CM, Sears MR. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. Eur Respir J. 1997;10:330-6.

Yates DH, Kharitonov SA, Barnes PJ. Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J. 1997;10:1483-8.

Adcock IM, Stevens DA, Barnes PJ. Interactions of glucocorticoids and beta 2-agonists. Eur Respir J. 1996;9:160-8.

Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol. 1996;144:1161-9.

Busse WW. Long-and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma. Arch Intern Med. 1996;156:1514-20.

Cockcroft DW, Swystun VA. Functional antagonism: tolerance produced by inhaled beta 2 agonists. Thorax. 1996;51:1051-6.

Eysmann SB, Gervino E, Vatner DE, et al. Prolonged exercise alters beta-adrenergic responsiveness in healthy sedentary humans. J Appl Physiol. 1996;80:616-22.

Garrett JE, Lanes SF, Kolbe J, Rea HH. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax. 1996;51:1093-9.

Giangrasso T. Prudent use of beta2-agonists in the treatment of asthma. N J Med. 1996;93:171-4.

Gustafson T, Boman K, Rosenhall L. Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Eur Respir J. 1996;9:237-40.

Hall IP. Beta 2 adrenoceptor polymorphisms: are they clinically important? [editorial]. Thorax. 1996;51:351-3.

Hayes MJ, Qing F, Rhodes CG, et al. In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Am J Respir Crit Care Med. 1996;154:1277-83.

Hjemdahl P, Zetterlund A, Larsson K. Beta 2-agonist treatment reduces beta 2-sensitivity in alveolar macrophages despite corticosteroid treatment. Am J Respir Crit Care Med. 1996;153:576-81.

Insel PA. Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors--evolving concepts and clinical implications. N Engl J Med. 1996;334:580-5.

Leff AR. Identifying patients at risk from the use of beta-adrenergic agonists [editorial; comment]. Am J Respir Crit Care Med. 1996;154:1593.

Malerba M, Boni E, Tantucci C, et al. Ineffectiveness of intravenous beta 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction. Respiration. 1996;63:8-16.

Marcelle R. Alpha-adrenergic bronchoconstriction in man. Arch Physiol Biochem. 1996;104:851-4.

O'Byrne PM, Kerstjens HA. Inhaled beta 2-agonists in the treatment of asthma [editorial; comment]. N Engl J Med. 1996;335:886-8.

Pino-Garcia JM, Garcia-Rio F, Gomez L, et al. Short-term effects of inhaled beta-adrenergic agonist on breathlessness and central inspiratory drive in patients with nonreversible COPD. Chest. 1996;110:637-41.

Roux FJ, Grandordy B, Douglas JS. Functional and binding characteristics of long-acting beta 2-agonists in lung and heart. Am J Respir Crit Care Med. 1996;153:1489-95.

Sears MR. Long-acting beta-agonists, tachyphylaxis, and corticosteroids [editorial; comment]. Chest. 1996;109:862-4.

Teramoto S, Fukuchi Y, Ouchi Y. A week-long course of inhaled beta-agonist or anticholinergic agent may reduce dyspnea during exercise in COPD [letter; comment]. Chest. 1996;109:1666-7.

Vichitvejpaisal P, Joshi GP, Kumar S, White PF. Effects of nebulized beta 2-adrenergic agonists on pulmonary mechanics in anesthetized patients with chronic obstructive pulmonary disease. J Med Assoc Thai. 1996;79:779-84.

Wilding PJ, Tattersfield AE. Interaction between corticosteroids and beta-agonists in asthma. Monaldi Arch Chest Dis. 1996;51:39-41.

Wolf BL, Landwehr LP. Agonizing over long-acting beta-agonists [letter]. J Allergy Clin Immunol. 1996;98:717-8.

Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med. 1995;152:838-60.

Barnes PJ. Molecular mechanisms of antiasthma therapy. Ann Med. 1995;27:531-5.

Boyd O, Lamb G, Mackay CJ, et al. A comparison of the efficacy of dopexamine and dobutamine for increasing oxygen delivery in high-risk surgical patients. Anaesth Intensive Care. 1995;23:478-84.

Bradding P. Anti-inflammatory effects of long-acting beta-agonists in asthma [editorial]. Clin Exp Allergy. 1995;25:912-4.

Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med. 1995;152:1485-9.

Coughlin SS, Metayer C, McCarthy EP, et al. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol. 1995;142:395-403.

Crane J, Pearce N, Burgess C, Beasley R. Asthma and the beta agonist debate. Thorax. 1995;50 Suppl 1:S5-10.

Fahy JV, Boushey HA. Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Clin Chest Med. 1995;16:715-33.

Fireman P. B2 agonists and their safety in the treatment of asthma. Allergy Proc. 1995;16:235-9.

Gilbert EM, Hershberger RE, Wiechmann RJ, et al. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995;108:1524-32.

Jay GT, Chow MS. Interaction of epinephrine and beta-blockers. JAMA. 1995;274:1830, 1832.

McFadden ER Jr. Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol. 1995;95:641-51.

Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med. 1995;333:499-506.

Nightingale CH. Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma. Pharmacotherapy. 1995;15:677-81.

Schmidt EW, Ulmer WT, Rominger KL. Pharmacokinetics and pharmacodynamics of beta 2-agonists (in the light of fenoterol). Respiration. 1995;62:190-200.

Skorodin MS. Asthma mortality and beta-agonists [letter; comment]. Chest. 1995;108:1768.

Tilles SA, Nelson HS. Long-acting inhaled beta agonists. J Asthma. 1995;32:397-404.

Ullman A. beta-Adrenoceptor agonists in future asthma therapy. Pharmacol Toxicol. 1995;77 Suppl 3:36-9.

Wanner A. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? Yes [editorial]. Am J Respir Crit Care Med. 1995;151:597-9.

Wanner A, Sears MR. Routine use of beta-adrenergic agonists in asthma [letter; comment]. Am J Respir Crit Care Med. 1995;152:823.

Wellman JJ. Long-acting inhaled beta agonists in the treatment of bronchial asthma [editorial; comment]. J Asthma. 1995;32:395-6.

Ziment I. The beta-agonist controversy. Impact in COPD. Chest. 1995;107:198S-205S.

Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J. 1994;7:569-78.

Barnes PJ; Airway pharmacology. In: Murray JF, Nadel JA, Ed. Textbook of Respiratory Medicine. 2 ed. Philadelphia: WB Saunders; 1994.

Fuller RW. Use of beta 2 agonists in asthma: much ado about nothing? Adverse effects are not proved. BMJ. 1994;309:795-6.

Tattersfield AE. Use of beta 2 agonists in asthma: much ado about nothing? Still cause for concern. BMJ. 1994;309:794-5.

Taylor DR, Sears MR. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest. 1994;106:552-9.

Anderson GP. Long acting inhaled beta-adrenoceptor agonists: the comparative pharmacology of formoterol and salmeterol. Agents Actions Suppl. 1993;43:253-69.

Chung KF. The current debate concerning beta-agonists in asthma: a review. J R Soc Med. 1993;86:96-100.

Gatto LA. Cholinergic and adrenergic stimulation of mucociliary transport in the rat trachea. Respir Physiol. 1993;92:209-17.

Johnson M. Beta 2-agonists as anti-inflammatory therapies in the lung. Agents Actions Suppl. 1993;41:27-45.

Lindner KH. Adrenergic agonist drug administration during cardiopulmonary resuscitation. Crit Care Med. 1993;21:S324-5.

Mortensen J, Hansen A, Falk M, et al. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest. 1993;103:805-11.

Nijkamp FP, Raaijmakers JAM. Beta-Receptor Agonists in Respiratory Disease. New York: Pergamon Press; 1993.

Ornato JP. Use of adrenergic agonists during CPR in adults. Ann Emerg Med. 1993;22:411-6.

Tattersfield AE. Clinical pharmacology of long-acting beta-receptor agonists. Life Sci. 1993;52:2161-9.

Bai TR. Beta-2 adrenergic receptors in asthma: a current perspective. Lung. 1992;170:125-41.

Burrows B, Lebowitz MD. The beta-agonist dilemma [editorial; comment]. N Engl J Med. 1992;326:560-1.

Haffner CA, Kendall MJ. Metabolic effects of beta-2 agonists. J Clin Pharm Ther. 1992;17:155-64.

Nathan RA. Beta 2 agonist therapy: oral versus inhaled delivery. J Asthma. 1992;29:49-54.

O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med. 1992;327:1204-8.

Page C, Costello J. Controversies in respiratory medicine: regular inhaled beta-agonists-- clear clinical benefit or a hazard to health? (2). Why beta-agonists should not be used regularly. Respir Med. 1992;86:477-9.

Pansegrouw DF. Acute resistant asthma caused by excessive beta-2-adrenoceptor agonist inhalation and reversed by inhalation of beclomethasone. S Afr Med J. 1992;82:179-82.

Sears MR, Taylor DR. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma [letter; comment]. Am Rev Respir Dis. 1992;145:734-5.

Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501-6.

Tattersfield AE. Long-acting beta 2-agonists. Clin Exp Allergy. 1992;22:600-5.

Twentyman OP, Higenbottam TW. Controversies in respiratory medicine: regular inhaled beta-agonists-- clear clinical benefit or a hazard to health? (1). Beta-agonists can be used safely and beneficially in asthma. Respir Med. 1992;86:471-6.

Hall JA. The cardiovascular effects of beta adrenergic agonist drugs administered by nebulization [letter; comment]. Postgrad Med J. 1991;67:211-2.

Lofdahl CG, Chung KF. Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J. 1991;4:218-26.

Mathewson HS. Adrenergic bronchodilators: trends in drug design. Respir Care. 1991;36:861-3.

Nelson HS, Szefler SJ, Martin RJ. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? [editorial]. Am Rev Respir Dis. 1991;144:249-50.

Pearce N, Crane J, Burgess C, Jackson R, Beasley R. Beta agonists and asthma mortality: deja vu. Clin Exp Allergy. 1991;21:401-10.

Rabe KF, Chung KF. The challenge of long-acting beta-adrenoceptor agonists. Respir Med. 1991;85:5-9.

Chung KF. Pharmacology of airway inflammation in asthma. Lung. 1990;168 Suppl:132-41.

Flatt A, Crane J, Purdie G, et al. The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation. Postgrad Med J. 1990;66:98-101.

Georgopoulos D, Wong D, Anthonisen NR. Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease. Chest. 1990;97:280-4.

Kemp JP, Meltzer EO. Beta 2 adrenergic agonists--oral or aerosol for the treatment of asthma? J Asthma. 1990;27:149-57.

Lemanske RF Jr, Joad J. Beta-2 receptor agonists in asthma: a comparison. J Asthma. 1990;27:101-9.

Nicklas RA. Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol. 1990;85:959-64.

Svedmyr N. Action of corticosteroids on beta-adrenergic receptors. Clinical aspects. Am Rev Respir Dis. 1990;141:S31-8.

Ziment I. Risk/benefit ratio of long-term treatment with beta 2-adrenoceptor agonists. Lung. 1990;168 Suppl:168-76.

Marsac JH, Vlastos FD, Lacronique JG. Inhaled beta adrenergic agonists and inhaled steroids in the treatment of asthma. Ann Allergy. 1989;63:220-4.

Ozog D, Lerner C. An exaggerated response to beta-adrenergics. Ann Allergy. 1989;62:11-3.

Coleman JJ, Vollmer WM, Barker AF, et al. Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline. Chest. 1986;90:45-51.

Popa V. Respiratory pharmacology. Beta-adrenergic drugs. Clin Chest Med. 1986;7:313-29.

Ebstein RP, Stessman J, Eliakim R, Menczel J. The effect of age on beta-adrenergic function in man: a review. Isr J Med Sci. 1985;21:302-11.

Nelson HS. Stepwise therapy of bronchial asthma: the role of beta-adrenergic agonists. Ann Allergy. 1985;54:289-93.

Tattersfield AE. Tolerance to beta-agonists. Bull Eur Physiopathol Respir. 1985;21:1s-5s.

Popa VT. Clinical pharmacology of adrenergic drugs. J Asthma. 1984;21:183-207.

Shim C. Adrenergic agonists and bronchodilator aerosol therapy in asthma. Clin Chest Med. 1984;5:659-68.

Bierman CW. Adrenergic drugs. Clin Rev Allergy. 1983;1:87-104.

Grogaard J, Sundell H. Effect of beta-adrenergic agonists on apnea reflexes in newborn lambs. Pediatr Res. 1983;17:213-9.

Mathewson HS. Evolution of beta adrenergic bronchodilators. Respir Care. 1983;28:777-79.

Canepa-Anson R, Dawson JR, Frankl WS, et al. Beta 2 adrenoceptor agonists. Pharmacology, metabolic effects and arrhythmias. Eur Heart J. 1982;3 Suppl D:129-34.

Eggleston PA, Beasley PP. Bronchodilation and inhibition of induced asthma by adrenergic agonists. Clin Pharmacol Ther. 1981;29:505-10.

Foster WM, Langenback EG, Bergofsky EH. Respiratory drugs influence lung mucociliary clearance in central and peripheral ciliated airways. Chest. 1981;80:877-80.

McFadden ER Jr. Beta 2 receptor agonist: metabolism and pharmacology. J Allergy Clin Immunol. 1981;68:91-7.

Maguire WC, Nair S. Ventilation and perfusion effects of inhaled alpha and beta agonists in asthma patients. Chest. 1978;73:983-5.

Plummer AL. Drug tolerance to beta2 adrenergic agents. Chest. 1978;73:994-6.

Plummer AL. The development of drug tolerance to beta2 adrenergic agents. Chest. 1978;73:949-57.

Sly RM. Effect of beta-adrenoreceptor stimulants on exercise-induced asthma. Pediatrics. 1975;56:910-5.

Srivastava BN, Shrivastava VK, Rao VS, et al. Beta adrenergic stimulant aerosols in bronchial asthma: an assessment. Indian J Chest Dis. 1973;15:123-31.

Compiled 7/30/99. Based on MedLine Update through June, 1999. A Scanlan Bibliography

Company | Contacts | Products | Sales